dc.contributor.author
Li, Lulu
dc.contributor.author
Zhang, Minli
dc.contributor.author
Su, Fuxiang
dc.contributor.author
Li, Yang
dc.contributor.author
Shen, Yali
dc.contributor.author
Shen, Jie
dc.contributor.author
Zhang, Daqing
dc.date.accessioned
2018-06-08T04:23:42Z
dc.date.available
2015-03-26T11:25:55.065Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/17201
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-21379
dc.description.abstract
Background Dyslipidemia management situation in Chinese patients with high
risk and very high risk has been demonstrated very low, despite the wide use
of statins. The effects and safety of the combined treatment of ezetimibe (EZ)
and statins in Chinese patients with acute coronary syndrome (ACS) and type 2
diabetes mellitus (T2DM) remain unknown. Methods Chinese Patients with ACS and
T2DM were divided into the statins group (n = 40) and the combination group of
EZ and statins (n = 44). In order to evaluate the clinical effects on lipids-
lowering, systemic inflammation response and clinical safety, the follow-up of
all patients was carried out at day 7th and 30th after treatment. Results The
level of low-density lipoprotein cholesterol (LDL-C) in combination group and
statins group was 1.87 ± 0.42 and 2.18 ± 0.58 mmol/L at day 7th, 1.51 ± 0.29
and 1.94 ± 0.49 mmol/L at day 30th, respectively. The control rates of LDL-C
level in the combination group and the statins group were 77% and 45% at day
30th, respectively. There was no significant improvement on high-density
lipoprotein cholesterol (HDL-C) level during follow-up. The triglyceride (TG)
levels were significantly reduced in both groups, while no obvious difference
was observed between two groups. No significant difference on serum high-
sensitivity C-reactive protein (hs-CRP) level between two groups was observed.
Moreover, we did not observe any significant correlation between serum lipids
levels and serum hs-CRP level during follow-up. The liver dysfunction and
muscle related side effects (MRSE), creatine kinase (CK) and myopathy were not
observed in both groups. Conclusion Our study demonstrated that it is feasible
to initiate combination therapy during acute phase for Chinese patients with
ACS and T2DM, which can bring more significant effect on LDL-C-lowering and
improve the control rate of LDL-C level with good safety.
en
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit
dc.title
Combination therapy analysis of ezetimibe and statins in Chinese patients with
acute coronary syndrome and type 2 diabetes
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
Lipids in Health and Disease. - 14 (2015), 1, Artikel Nr. 10
dcterms.bibliographicCitation.doi
10.1186/s12944-015-0004-7
dcterms.bibliographicCitation.url
http://www.lipidworld.com/content/14/1/10
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000022104
refubium.note.author
Der Artikel wurde in einer Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000004709
dcterms.accessRights.openaire
open access